Smoldering Multiple Myeloma

"Smoldering Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.

Descriptor ID	D000075122
MeSH Number(s)	C04.834.794 C15.378.147.542.820 C15.378.147.780.838 C20.683.460.820 C20.683.780.838
Concept/Terms	Smoldering Multiple Myeloma Smoldering Multiple Myeloma Multiple Myeloma, Smoldering Smoldering Multiple Myelomas Smoldering Myeloma Myeloma, Smoldering Smoldering Myelomas Asymptomatic Multiple Myeloma Asymptomatic Multiple Myelomas Multiple Myeloma, Asymptomatic Multiple Myelomas, Asymptomatic

Below are MeSH descriptors whose meaning is more general than "Smoldering Multiple Myeloma".

Diseases [C]
Neoplasms [C04]
Precancerous Conditions [C04.834]
Smoldering Multiple Myeloma [C04.834.794]
Hemic and Lymphatic Diseases [C15]
Hematologic Diseases [C15.378]
Blood Protein Disorders [C15.378.147]
Hypergammaglobulinemia [C15.378.147.542]
Smoldering Multiple Myeloma [C15.378.147.542.820]
Paraproteinemias [C15.378.147.780]
Smoldering Multiple Myeloma [C15.378.147.780.838]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Hypergammaglobulinemia [C20.683.460]
Smoldering Multiple Myeloma [C20.683.460.820]
Paraproteinemias [C20.683.780]
Smoldering Multiple Myeloma [C20.683.780.838]

Below are MeSH descriptors whose meaning is more specific than "Smoldering Multiple Myeloma".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Smoldering Multiple Myeloma" by people in this website by year, and whether "Smoldering Multiple Myeloma" was a major or minor topic of these publications.

Bar chart showing 5 publications over 4 distinct years, with a maximum of 2 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2018	1	0	1
2020	1	1	2
2022	1	0	1
2024	1	0	1

Below are the most recent publications written about "Smoldering Multiple Myeloma" by people in Profiles.

Kazandjian D, Diamond B, Papadimitriou M, Hill E, Sklavenitis-Pistofidis R, Ziccheddu B, Blaney P, Chojnacka M, Durante M, Maclachlan K, Young R, Usmani S, Davies F, Getz G, Ghobrial I, Korde N, Morgan G, Maura F, Landgren O. Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Clin Cancer Res. 2024 Oct 01; 30(19):4482-4490.

View in: PubMed
Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.

View in: PubMed
Gran C, Luong V, Bruchfeld JB, Liwing J, Afram G, Lund J, Usmani S, Alici E, Nahi H. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. Am J Hematol. 2021 03 01; 96(3):E63-E65.

View in: PubMed
Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.

View in: PubMed
Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, Salem K, Tai YT, Anand S, Mouhieddine TH, Chavda SJ, Boehner C, Elagina L, Neuse CJ, Cha J, Rahmat M, Taylor-Weiner A, Van Allen E, Kumar S, Kastritis E, Leshchiner I, Morgan EA, Laubach J, Casneuf T, Richardson P, Munshi NC, Anderson KC, Trippa L, Aguet F, Stewart C, Dimopoulos MA, Yong K, Bergsagel PL, Manier S, Getz G, Ghobrial IM. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.

View in: PubMed
Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, Usmani SZ, Bhutani M. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J. 2018 11 08; 8(11):107.

View in: PubMed

People

Usmani, Saad

Explore

Similar Concepts

Top Journals